Articles where Melior, or our drug discovery approach, was featured.
By Moon-Kyu Lee, Sin Gon Kim, Elaine Watkins, Min Kyong Moon, Sang Youl Rhee, Juan P. Frias, Choon Hee Chung, Seung-Hwan Lee, Bradley Block, Bong Soo Cha, Hyeong Kyu Park, Byung Joon Kim, Frank Greenway
Journal of Diabetes and Its Complications, 2020
Melior Discovery’s first repositioned drug, identified with theraTRACE®, is clinically validated.
By Dr Stephen Naylor and Dr Kirkwood A. Pritchard Jr
Drug Discovery World, Spring 2019
This paper favorably features Melior Discovery’s business model.
By Mihaly Szabo, Sara Svensson sjärvi, Ankur Saxena, Jianping Liu,
Gayathri Chandrasekar, Satish S. Kitambi
Drug Design, Development & Theory, June 2017
The phenotype-based drug discovery (PDD) approach is re-emerging as an alternative platform for drug discovery.
Therapeutic Drug Repurposing, Repositioning and Rescue Part II: Business Review
By Dr Stephen Naylor, David M. Kauppi & Judge M. Schonfeld
Drug Discovery World, Spring 2015
There is an emerging consensus that the impact of Drug Repurposing, Repositioning and Rescue (DRPx) on the pharmaceutical industry is real and sustainable.
Therapeutic Drug Repurposing, Repositioning and Rescue Part I: Overview
By Dr Stephen Naylor and Judge M. Schonfeld
Drug Discovery World, Winter 2014
The pharmaceutical industry is still beleaguered by escalating costs, stagnant productivity and protracted timelines as it struggles to bring therapeutic drugs to market.
A Forensic Analysis of Drug Targets From 2000 Through 2012
By B. Munos
Clinical Pharmacology & Therapeutics June 2013
Pharmaceutical innovation is often measured by counting the new drugs approved by regulators. It is a simple and useful metric, but it has shortcomings. One of them is that it says little about the drugs’ innovativeness. […]
Exploiting Complexity and the Robustness of Network Architecture for Drug Discovery
By Marc K. Hellerstein
JPET, January 2008
The issue of complexity stands at the center of contemporary drug discovery and development. The central problem in drug development today is attrition of drug candidates identified by the modern molecular target-based discovery approach […]
Christopher Lipinski, PhD Named in Top Ten Most Influential People in Pharma
World Pharmaceutical Frontiers 2007 Edition Pharma 40
The Pharma 40 has been a great opportunity to evaluate the figures who have the bigest impact on our industry – an to see the sheer scope of their different influences. But when the votes came in, we had to triple-check our figures – not just for accuracy, but because the top spot was such a surprise […]